LX-2761 - CAS 1610954-97-6
Catalog: |
BB011698 |
Product Name: |
LX-2761 |
CAS: |
1610954-97-6 |
Synonyms: |
LX2761 |
IUPAC Name: | N-[2-(dimethylamino)ethyl]-2-methyl-2-[4-[4-[[2-methyl-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]phenyl]methyl]phenyl]butanoylamino]propanamide |
Description: | LX-2761 is a locally acting SGLT1 inhibitor that can delay intestinal glucose absorption in the body to improve blood sugar control. |
Molecular Weight: | 601.8 |
Molecular Formula: | C32H47N3O6S |
Canonical SMILES: | CC1=C(C=C(C=C1)C2C(C(C(C(O2)SC)O)O)O)CC3=CC=C(C=C3)CCCC(=O)NC(C)(C)C(=O)NCCN(C)C |
InChI: | InChI=1S/C32H47N3O6S/c1-20-10-15-23(29-27(38)26(37)28(39)30(41-29)42-6)19-24(20)18-22-13-11-21(12-14-22)8-7-9-25(36)34-32(2,3)31(40)33-16-17-35(4)5/h10-15,19,26-30,37-39H,7-9,16-18H2,1-6H3,(H,33,40)(H,34,36)/t26-,27-,28+,29+,30-/m1/s1 |
InChI Key: | BNPZTRDIESRGTC-IXYVTWBDSA-N |
Boiling Point: | 843.9±65.0 ℃ (Predicted) |
Purity: | ≥ 98 % by HPLC |
Density: | 1.24±0.1 g/cm3(Predicted) |
Solubility: | Soluble in DMSO |
Storage: | Store at -20 ℃ |
LogP: | 3.10600 |
Publication Number | Title | Priority Date |
WO-2020200153-A1 | Glucoside derivative that acts as sglt1 inhibitor and application thereof | 20190329 |
WO-2020068661-A1 | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis | 20180926 |
US-2020255394-A1 | Crystalline solid forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis | 20180926 |
CA-3113037-A1 | Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis | 20180926 |
US-10968192-B2 | Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis | 20180926 |
PMID | Publication Date | Title | Journal |
5021 | 19751201 | [Comparative study of nitrogen savings during enteral and parenteral feeding (Trive 1000)] | Annales de l'anesthesiologie francaise |
Complexity: | 852 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 5 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 601.3185574 |
Formal Charge: | 0 |
Heavy Atom Count: | 42 |
Hydrogen Bond Acceptor Count: | 8 |
Hydrogen Bond Donor Count: | 5 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 601.3185574 |
Rotatable Bond Count: | 13 |
Topological Polar Surface Area: | 157 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 2.5 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Carbonyl Compounds
Customers Also Viewed
-
[133407-82-6]
MG-132
-
[875573-66-3]
Estra-1,3,5(10)-triene-3,17-diol,7-(9-bromononyl)-,17-acetate,(7a,17b)-
-
[1263166-91-1]
endo-BCN-PNP-carbonate
-
[44994-28-7]
N,N,N',N'-Tetramethyl-1,5-pentanediamine
-
[2555-49-9]
Ethyl phenoxyacetate
-
[10128-55-9]
N-[2-(4-oxo-4H-3,1-benzoxazin-2-yl)phenyl]-2-naphthalenesulfonamide
INDUSTRY LEADERS TRUST OUR PRODUCTS